2017 ACAAI Annual Meeting On Demand: General Sessions

Cost: $285 for College Members, $350 for non-members.

You can earn up to 37 AMA PRA Category 1 Credits™, and up to a maximum of 11 MOC Part II Self-Assessment credits. This collection covers general sessions from Thursday, Friday, Saturday, Sunday, and Monday's program; including, plenaries, symposia, and the Thursday Program.

Release Date: 11/20/2017
Expiration Date: 11/19/2020

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 37 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Of the AMA PRA Category 1 Credits™ listed above, the ABAI has designated a maximum of 11 credits as meeting the requirements for MOC Part II Self-Assessment.

Target Audience

Medical professionals who treat patients with allergic and/or immunological conditions:

  • Practicing allergist/immunologists
  • Allergy/immunology Fellows-in-Training
  • Physician assistants
  • Nurses and advanced practice nurses
  • Allied health professionals
  • Primary care physicians
  • Other medical professionals

Learning Objectives

At the conclusion of this activity, participants should be able to:

  • Identify major advances in key areas of cutting edge research in immunologic mechanisms and allergic responses, including anaphylaxis and pathophysiology of the upper airways, lungs, eyes, skin and gastrointestinal tract.
  • Demonstrate knowledge of basic processes linking molecular and cellular biology and genetics with allergic pathophysiology and immunodeficiency.
  • Translate emerging clinical science principles to clinical practice in patients with allergic and immunologic diseases.
  • Evaluate and implement state-of-the-art diagnostic and therapeutic strategies for treating patients with allergic and immunologic diseases.
  • Explain the impact of environmental exposures and external influences on patients with allergic disorders.
  • Recognize emerging trends in the prevalence of allergic and immunologic disorders and discuss their impact on public health.
  • Evaluate the impact of new diagnostic and therapeutic strategies on health care costs and outcomes.
  • Discuss processes, tools and technologies for the efficient allergy and immunology practice.
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (College) policy, the College must identify and resolve conflicts of interest for all individuals responsible for the development, management, presentation, or evaluation of content for a CME activity. Financial disclosures are reviewed in advance, to ensure any potential conflicts of interest are resolved. Disclosure in no way implies that the information presented is biased or of lesser quality; it is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Specific disclosure information for the 2017 Annual Meeting is conveniently located online at college.acaai.org/disclosures

The live activity was supported by independent educational grants from the following commercial supporters:

  • Moving Toward Precision Medicine in Atopic Dermatitis and Food Allergy: Supported by an independent educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals
  • New Horizons in Food Allergy: Supported by an independent educational grant from Aimmune Therapeutics
  • Anaphylaxis: Causes, Diagnosis and Management: Supported by an independent educational grant from Mylan
  • Which T2 Biologic is Best Suited for GINA 4-5 Non-responders?: Supported by an independent educational grant from GlaxoSmithKline
  • The Asthmatic Who Does Not Qualify for a T2 Biologic: What Is Next?: Supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Course summary
Available credit: 
  • 37.00 AMA PRA Category 1 Credit™
  • 37.00 Attendance
Course opens: 
11/01/2017
Course expires: 
11/19/2020
Cost:
$350.00
Rating: 
0

Available Credit

  • 37.00 AMA PRA Category 1 Credit™
  • 37.00 Attendance

Accreditation Period

Course opens: 
11/01/2017
Course expires: 
11/19/2020
 
Status
Price
Title
$0.00Included
Please login or create an account to take this course.
$0.00Included
Please login or create an account to take this course.
$0.00Included
Please login or create an account to take this course.
$0.00Included
Please login or create an account to take this course.
$0.00Included
Please login or create an account to take this course.

Price

Cost:
$350.00
Please login or create an account to take this course.